Let’s not kid ourselves: medical access is merely a stepping stone to legality.
For its fifth installment, Psychedelic Science 2025 returned to Denver, offering three days of big ideas, heartfelt community, and some noticeable shifts in the psychedelic space. After the usual chaos of delayed flights and travel drama on Tuesday, we shared a collective sigh of relief as we finally arrived at the Colorado Convention Center, a mile high and ready to dive in.
Mindstate Design Labs has received approval for a Phase 1 clinical trial to investigate the use of its formulation of 5-MeO-MiPT which it hopes to combine with other drugs to target precise serotonin receptors and create future psychotropic therapies.
Elizabeth Nielson, co-founder of Fluence, offers thoughts on the roll out of the 2025 psychedelic therapy program in Colorado and the opportunities it offers for mental health professionals.
Here, we explore the settlement as well as the potential repercussions for other religious groups that seek to use psychedelics as part of their practices. We also share a response from certain…
In part one of a series of articles on ibogaine clinics, researcher Leonard Pickard looks at the history and treatment protocols of clinics in Mexico, Brazil and Portugal.